GLPBio

GRGDSP

Catalog No.: GC33323Purity:>98.00%
COASDSData Sheet
합성 선형 RGD 펩티드인 GRGDSP는 인테그린 억제제입니다.

제품은 연구용으로만 사용됩니다. 인체에 사용할 수 없으며 환자에게 판매하지 않습니다.

GRGDSP
Cas No.: 91037-75-1
1mgIn Stock
$28.00
1
5mgIn Stock
$73.00
1
10mgIn Stock
$111.00
1
25mgIn Stock
$202.00
1
50mgIn Stock
$280.00
1
100mgIn Stock
$392.00
1
Tel: (909) 407-4943 / (909) 689-7124Email: sales@glpbio.com

인용 문헌 (Citations)

현재 이 제품에 대한 인용 문헌이 없습니다. 아래는 GlpBio 제품을 인용한 주요 논문입니다.
  • Nature cover
    Nature
    641, 529–536 (2025)
  • Nature cover
    Nature
    628, 630–638 (2024)
  • Nature cover
    Nature
    632, 686–694 (2024)
  • Nature cover
    Nature
    618, 1017–1023 (2023)
  • Nature cover
    Nature
    610, 366–372 (2022)
  • Cell cover
    Cell
    187(9):2288-2304 (2024)
  • Cell cover
    Cell
    183(7):1867-1883 (2020)
  • Science cover
    Science
    388(6745) (2025)
  • Science cover
    Science
    387(6739) (2025)
  • Science cover
    Science
    387(6734) (2025)
  • Cell Research cover
    Cell Research
    35, 97–116 (2025)
  • Cell Research cover
    Cell Research
    34, 683–706 (2024)
  • Cell Research cover
    Cell Research
    33, 273–287 (2023)
  • Cell Research cover
    Cell Research
    33, 546–561 (2023)
  • Cell Research cover
    Cell Research
    33, 904–922 (2023)
  • Cell Research cover
    Cell Research
    31, 1291–1307 (2021)

제품 설명 (Description)

GRGDSP, a synthetic linear RGD peptide, is an integrin inhibitor [1]. GRGDSP can induce cells to become round and activate matrix metalloproteinase-2 (MMP-2), thereby increasing the levels of membrane-bound precursors and active forms of MMP-1 and MMP-2 [2]. GRGDSP has been used to modify the surface of cardiovascular implants such as vascular grafts to promote endothelialization [3].

In vitro, GRGDSP treatment (5mM) for 48h significantly inhibited the viability of rabbit chondrocytes and synovial cells, accompanied by an increase in Caspase-3 activity[4]. 10nM of GRGDSP treatment for 24 hours significantly promoted the migration of human foreskin fibroblasts (HFF)[5].

In vivo, GRGDSP treatment via administration (1mg/kg/day) at the injured site for 14 days significantly delayed the remyelination in Dhhcre/+;Ninj2fl/fl mice and reduced motor coordination and locomotion in mice [6]. A single arterial infusion of 0.25mg of GRGDSP combined with transarterial chemoembolization (TACE) inhibited the invasive growth and metastasis of tumor cells in rats with hepatic carcinoma within 12 days[7].

References:
[1] Qian J, Oppermann E, Tran A, et al. Transarterial administration of integrin inhibitor loaded nanoparticles combined with transarterial chemoembolization for treating hepatocellular carcinoma in a rat model[J]. World Journal of Gastroenterology, 2016, 22(21): 5042.
[2] Teti A, Farina A R, Villanova I, et al. Activation of MMP‐2 by human GCT23 giant cell tumour cells induced by osteopontin, bone sialoprotein and GRGDSP peptides is RGD and cell shape change dependent[J]. International journal of cancer, 1998, 77(1): 82-93.
[3] Patel S, Tsang J, Harbers G M, et al. Regulation of endothelial cell function by GRGDSP peptide grafted on interpenetrating polymers[J]. Journal of Biomedical Materials Research Part A: An Official Journal of The Society for Biomaterials, The Japanese Society for Biomaterials, and The Australian Society for Biomaterials and the Korean Society for Biomaterials, 2007, 83(2): 423-433.
[4] Matsuki K, Sasho T, Nakagawa K, et al. RGD peptide-induced cell death of chondrocytes and synovial cells[J]. Journal of Orthopaedic Science, 2008, 13(6): 524-532.
[5] Knapp D M, Helou E F, Tranquillo R T. A fibrin or collagen gel assay for tissue cell chemotaxis: assessment of fibroblast chemotaxis to GRGDSP[J]. Experimental cell research, 1999, 247(2): 543-553.
[6] Sun Y, Chen X, Yue C, et al. Ninj2 regulates Schwann cells development by interfering laminin-integrin signaling[J]. Theranostics, 2022, 12(17): 7307.
[7] Qian J, Yin J, Liang H, et al. Experimental study on transarterial administration of GRGDSP combined with transarterial chemoembolization in rats with hepatic carcinoma[J]. Cardiovascular and interventional radiology, 2008, 31(2): 377-382.

실험 프로토콜 (Protocol)

Cell experiment [1]:

Cell lines

 Rabbit synovial cells

Preparation Method

 Rabbit synovial cells were cultivated in RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum (FBS), 100units/ml penicillin, and 100mg/ml streptomycin at 37°C in an incubator with 5% CO2. Cells were seeded in a 12-well plate at a density of 2×105 cells/well for 24h. Cells were treated with 5mM GRGDSP and serum-free medium. After 48h of treatment, the cell viability was determined.

Reaction Conditions

 5mM; 48h

Applications

 GRGDSP treatment significantly inhibited cell viability of rabbit synovial cells.
Animal experiment [2]:

Animal models

 Male Wistar rats

Preparation Method

 Male Wistar rats (180-220g) were maintained in a controlled environment at 22±3°C and 60% relative humidity under a 12h light/dark cycle, and were given free access to standard rodent nutrition and water. Walker-256 tumor tissue was recovered from a propagation animal 10 days after subcutaneous implantation and cut into small cubes approximately 2mm3 in volume. The rats were anesthetized, the abdominal wall was opened, and a small subcapsular incision was made on the left lateral lobe of the liver. The tumor fragment was gently placed into the pocket and covered with a small piece of a cotton swab on the liver surface. The abdominal wall was subsequently closed. Using a binocular operative microscope, a PE-10 polyethylene microcatheter (inner diameter 0.28mm, outer diameter 0.61mm) was retrogradely inserted via the gastroduodenal artery into the hepatic artery. The therapeutic agents were mixed and then injected into the hepatic artery within 20min. Each group received treatment according to the following protocols: Group A (GRGDSP + TACE; n = 9): 0.05ml mitomycin (1mg/ml) + 0.1ml GRGDSP (2.5mg/ml) + 0.05ml lipiodol + ligation of the proper hepatic artery; Group B (TACE alone; n = 8): 0.05ml mitomycin (1 mg/ml) + 0.05ml lipiodol + ligation of the proper hepatic artery; Group C (normal saline; n = 9): 0.2ml 0.9% NaCl. Twelve days after interventional therapy, MRI examination was again performed, and the post-treatment volume of the hepatic tumor (V2) was measured.

Dosage form

 2.5mg/ml (0.1ml) for once; hepatic artery administration

Applications

 GRGDSP treatment significantly inhibited combined with TACE inhibited the hepatic carcinoma growth in rats.

References:
[1] Matsuki K, Sasho T, Nakagawa K, et al. RGD peptide-induced cell death of chondrocytes and synovial cells[J]. Journal of Orthopaedic Science, 2008, 13(6): 524-532.
[2] Qian J, Yin J, Liang H, et al. Experimental study on transarterial administration of GRGDSP combined with transarterial chemoembolization in rats with hepatic carcinoma[J]. Cardiovascular and interventional radiology, 2008, 31(2): 377-382.

제품 문서 (Product Documents)

Purity:>98.00%Appearance:A solid
COASDSData Sheet

화학적 특성 (Chemical Properties)

CAS 번호
91037-75-1
SMILES
Gly-Arg-Gly-Asp-Ser-Pro
분자식
C22H37N9O10
분자량
587.58
용해도
Soluble in DMSO
보관
Store at -20°C
일반 주의사항
제품의 용해도 데이터에 따라 적절한 용매를 선택하십시오. 조제 후에는 반복적인 동결·해동을 피할 수 있도록 저장 용액을 소분하십시오.
저장 용액은 -80°C 보관 시 6개월 이내, -20°C 보관 시 1개월 이내에 사용하십시오.
용해도를 높이려면 튜브를 37°C로 데운 뒤 적절한 시간 동안 초음파 처리하십시오.
배송 조건
평가용 샘플은 아이스팩과 함께 배송됩니다. 그 외 용량은 실온 배송되며, 요청 시 아이스팩과 함께 배송할 수 있습니다.

계산 도구 (Calculators)몰 농도 / 희석 / 분자량 / 단위 변환 / 생체 내 제형 / 용해도

g/mol

Reviews

Review for GRGDSP

Rating: 5
  • 5 Star100%
  • 4 Star0%
  • 3 Star0%
  • 2 Star0%
  • 1 Star0%